Our first product.
- GrB-Fc-SD1 is a fusion of Granzyme B (GrB) to a single domain antibody that targets mesothelin (SD1).
- Mesothelin is expressed on various types of cancers. Pancreatic, lung, ovarian, and mesothelioma are of interest because of unmet needs for effective therapies.
- Mesothelin plays a role in cancer progression by aiding metastasis, promoting tumor survival and proliferation, and drug resistance.
- Mesothelin has been validated as a cancer therapeutic target with various therapeutic strategies in preclinical and clinical development.
- GrB-Fc-SD1 has been produced, characterized, and evaluated for tumor cytotoxicity.
- IC50 cytotoxicity for 14 human lung and pancreatic tumor cells is in the nM range.
